One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost–benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)
Vittorio Fusco, Giuseppina Campisi, Alberto Bedogni
Topics & Concepts
DenosumabMedicineZoledronic acidOsteonecrosis of the jawOncologyIntensive care medicineBisphosphonateQuality of life (healthcare)Internal medicineOsteoporosisNursingBone health and treatmentsCancer Diagnosis and TreatmentRadiopharmaceutical Chemistry and Applications